Antimicrobal resistance of nosocomial carbapenemase-producing Enterobacterales in Russia: results of surveillance, 2014-2016

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(4):362-369

​ Shajdullina E.R., Edelstein M.V., Skleenova E.Yu., Sukhorukova M.V., Kozlov R.S.
10.36488/cmac.2018.4.362-369
Enterobacterales carbapenemases nosocomial infections ceftazidime/avibactam aztreonam/avibactam
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(4):362-369

Objective.

To assess the prevalence and antimicrobial susceptibility of carbapenemase-producing Enterobacterales (CPE).

Materials and Methods.

A total of 5539 Enterobacterales isolates recovered from hospitalized patients in 52 medical institutions in 27 cities in Russia in 2014-2016 were tested. Antibiotic susceptibility testing (AST) was performed using broth microdilution method according to ISO 20776-1:2006. Avibactam was tested in combinations with beta-lactams at fixed concentration of 4 mg/l. AST results were interpreted according to EUCAST v8.1 clinical breakpoints. Carbapenemase production was assessed by carbapenem inactivation method (CIM). Genes for the most common carbapenemases: NDM, VIM, IMP, KPC, and OXA-48, were detected by real-time PCR. Carbapenemase-producing isolates of Klebsiella pneumoniae were subtyped by multilocus sequence typing (MLST).

Results.

CPE comprised 9.9% of all tested isolates. 7.7% of the isolates were found to produce serinebased carbapenemases of OXA-48 group, 1.9% – metallo-beta-lactamases of NDM group, 0.3% – to co-produce of OXA-48 and NDM. Ceftazidime/avibactam and aztreonam/avibactam demonstrated the highest in vitro activity by inhibited growth of 78.1% (at ≤4 mg/L ceftazidime concentration) and 99.3% (at ≤4 mg/L aztreonam concentration) of the CPE isolates, respectively. Moreover, 94.5% of carbapenemase producers were susceptible to aztreonam/avibactam at ≤0.5 mg/L aztreonam concentration. Among nonbeta-lactam agents, tigecyclin was the most active with 84.8% susceptibility rate. Notably, 11.0% of all CPE were categorized as extensively drug-resistant (XDR).

Conclusions.

This study shows sharp increase in the prevalence of CPE in Russian hospitals. Carbapenemases of the OXA-48 group were the most prevalent in Enterobacterales followed by NDM. Among all antibiotics tested against CPE isolated from hospitalized patients, combinations of avibactam with ceftazidime and aztreonam were the most active in vitro.

Elvira R. Shajdullina

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia
Kazan (Volga Region) Federal University, Kazan, Russia

Mikhail V. Edelstein

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

Elena Yu. Skleenova

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

Marina V. Sukhorukova

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk State Medical University, Smolensk, Russia

  • 1. Sukhorukova M.V., Edelstein M.V., Skleenova E.Yu., et al. Antimicrobial resistance of nosocomial Enterobacteriaceae isolates in Russia: results of multicenter epidemiological study “MARAFON” 2013-2014. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2014;16:254-265. Russian.
  • 2. Sukhorukova M.V., Edelstein M.V., Skleenova E.Yu., et al. Antimicrobial resistance of nosocomial Enterobacteriaceae isolates in Russia: results of multicenter epidemiological study “MARAFON” 20132014. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19:49-56. Russian.
  • 3. Sukhorukova M., Kozyreva V., Ivanchik N., et al. Five-year trends in the prevalence and types of ESBLs and antimicrobial susceptibility of ESBL-producing nosocomial strains of Enterobacteriaceae in Russia. 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria; 10-13 April 2010. Abstract P716.
  • 4. Coque T.M., Baquero F., Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008;13(47):pii:19044.
  • 5. Doi Y., Iovleva A., Bonomo R.A. The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world. J Travel Med. 2017;24(Suppl 1):S44-S51.
  • 6. Albiger B., Glasner C., Struelens M., et al. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill. 2015;20(45).
  • 7. Nordmann P., Poirel L. The difficult-to-control spread of carbapenemaseproducing among Enterobacteriaceae worldwide. Clin Microbiol Infect. 2014;20(9):821-830.
  • 8. Mariappan S., Sekar U., Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes. Int J Appl Basic Res. 2017;7(1):32-3
  • 9. Sotgui, G. Are B.M., Pesapane L. Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study. J Hosp Infect. 2018;99(4):413-418. DOI: 10.1016/j.jhin.2018.03.033
  • 10. WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017. – Available at: http://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-newantibiotics-are-urgently-needed. Accessed January 28, 2019.
  • 11. GOST R ISO 20776-1-2010 Clinical laboratory testing and in vitro diagnostic test systems. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 1. Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infection us diseases. Russian.
  • 12. ISO 20776-1:2006 “Clinical laboratory testing and in vitro diagnostic test systems – Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices – Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases”.
  • 13. European Committee on Antimicrobial Susceptibility testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Ver. 8.1. 2018. Available at: www.eucast.org/clinical_breakpoints/. Accessed November 27, 2018.
  • 14. Clinical recommendations. Susceptibility testing of microorganisms to antimicrobial agents. Ver. 2015-02. Available at: www.antibiotic.ru/minzdrav/files/docs/clrec-dsma2015.pdf. Accessed November 27, 2018. Russian.
  • 15. van der Zwaluw K., de Haan A., Pluister G.N., et al. Carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in Gramnegative rods. PLoS One. 2015;10(3):e0123690.
  • 16. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Ver 2.0. 20
  • 17. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf. Accessed January 28, 2019.
  • 18. Diancourt L., Passet V., Verhoef J., Grimont P.A., Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005;43(8):4178-4182.
  • 19. Kuzmenkov A.Yu., Trushin I.V., Avramenko A.A., et al. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90. Russian.
  • 20. Magiorakos A.P., Srinivasan A., Carey R.B., et al. Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared